CO5560585A2 - Formulacion farmaceutica para administracion intramuscular de fulvestrant - Google Patents
Formulacion farmaceutica para administracion intramuscular de fulvestrantInfo
- Publication number
- CO5560585A2 CO5560585A2 CO04000761A CO04000761A CO5560585A2 CO 5560585 A2 CO5560585 A2 CO 5560585A2 CO 04000761 A CO04000761 A CO 04000761A CO 04000761 A CO04000761 A CO 04000761A CO 5560585 A2 CO5560585 A2 CO 5560585A2
- Authority
- CO
- Colombia
- Prior art keywords
- weight
- per volume
- formulation vehicle
- formulation
- fulvestrant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0116619.8A GB0116619D0 (en) | 2001-07-07 | 2001-07-07 | Formulation |
| US31571101P | 2001-08-30 | 2001-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5560585A2 true CO5560585A2 (es) | 2005-09-30 |
Family
ID=26246290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04000761A CO5560585A2 (es) | 2001-07-07 | 2004-01-07 | Formulacion farmaceutica para administracion intramuscular de fulvestrant |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1406662A1 (is) |
| JP (1) | JP2004534093A (is) |
| CN (1) | CN1553815A (is) |
| AR (1) | AR037138A1 (is) |
| BR (1) | BR0210898A (is) |
| CA (1) | CA2453111A1 (is) |
| CO (1) | CO5560585A2 (is) |
| HU (1) | HUP0400115A3 (is) |
| IL (1) | IL159576A0 (is) |
| IS (1) | IS7097A (is) |
| MX (1) | MXPA04000028A (is) |
| NO (1) | NO20040047L (is) |
| PL (1) | PL367624A1 (is) |
| RU (1) | RU2004102393A (is) |
| WO (1) | WO2003006064A1 (is) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| US8586092B2 (en) | 2009-08-31 | 2013-11-19 | Xi'an Libang Pharmaceutical Technology Co., Ltd. | Fulvestrant nanosphere/microsphere and preparative method and use thereof |
| CN102600073B (zh) * | 2012-03-31 | 2014-01-01 | 莱普德制药有限公司 | 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法 |
| CN102600065B (zh) * | 2012-03-31 | 2014-08-13 | 莱普德制药有限公司 | 一种氟维司群或其衍生物油性制剂及其制备方法 |
| CN102600064A (zh) * | 2012-03-31 | 2012-07-25 | 西安力邦制药有限公司 | 氟维司群或其衍生物缓释制剂及其制备方法 |
| US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
| JP6682163B2 (ja) * | 2016-04-06 | 2020-04-15 | 富士フイルム株式会社 | 医薬組成物 |
| US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| MX2018013414A (es) * | 2016-05-06 | 2019-06-06 | Eagle Pharmaceuticals Inc | Formulaciones de fulvestrant y metodos para su uso. |
| CN109152785B (zh) | 2016-05-31 | 2021-02-09 | 富士胶片株式会社 | 医药组合物 |
| JP7220712B2 (ja) * | 2017-11-08 | 2023-02-10 | イーグル ファーマスーティカルズ、インク． | フルベストラント製剤とその使用方法 |
| US20210169897A1 (en) * | 2017-12-07 | 2021-06-10 | Nevakar Inc. | Concentrated Fulvestrant Compositions |
| WO2019151353A1 (ja) * | 2018-01-31 | 2019-08-08 | 富士フイルム株式会社 | 注射用製剤の製造方法 |
| CN111481559B (zh) * | 2019-01-25 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种高浓度的氟维司群组合物及其制备方法 |
| US20220370359A1 (en) * | 2019-12-11 | 2022-11-24 | Shanghai Bocimed Pharmaceutical Co., Ltd. | Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8813353D0 (en) * | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
| GB9525194D0 (en) * | 1995-12-12 | 1996-02-07 | Zeneca Ltd | Pharmaceutical composition |
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| GB0008172D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Therapy |
-
2002
- 2002-07-03 IL IL15957602A patent/IL159576A0/xx unknown
- 2002-07-03 PL PL02367624A patent/PL367624A1/xx not_active Application Discontinuation
- 2002-07-03 EP EP02740940A patent/EP1406662A1/en not_active Withdrawn
- 2002-07-03 CN CNA028171888A patent/CN1553815A/zh active Pending
- 2002-07-03 CA CA002453111A patent/CA2453111A1/en not_active Abandoned
- 2002-07-03 BR BR0210898-4A patent/BR0210898A/pt not_active IP Right Cessation
- 2002-07-03 RU RU2004102393/15A patent/RU2004102393A/ru not_active Application Discontinuation
- 2002-07-03 JP JP2003511869A patent/JP2004534093A/ja active Pending
- 2002-07-03 WO PCT/GB2002/003092 patent/WO2003006064A1/en not_active Application Discontinuation
- 2002-07-03 HU HU0400115A patent/HUP0400115A3/hu unknown
- 2002-07-05 AR ARP020102523A patent/AR037138A1/es not_active Application Discontinuation
-
2004
- 2004-01-05 IS IS7097A patent/IS7097A/is unknown
- 2004-01-06 NO NO20040047A patent/NO20040047L/no not_active Application Discontinuation
- 2004-01-07 MX MXPA04000028A patent/MXPA04000028A/es unknown
- 2004-01-07 CO CO04000761A patent/CO5560585A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IS7097A (is) | 2004-01-05 |
| CA2453111A1 (en) | 2003-01-23 |
| JP2004534093A (ja) | 2004-11-11 |
| MXPA04000028A (es) | 2004-05-21 |
| WO2003006064A1 (en) | 2003-01-23 |
| NO20040047L (no) | 2004-02-23 |
| RU2004102393A (ru) | 2005-03-27 |
| BR0210898A (pt) | 2004-06-22 |
| IL159576A0 (en) | 2004-06-01 |
| EP1406662A1 (en) | 2004-04-14 |
| HUP0400115A2 (hu) | 2004-06-28 |
| AR037138A1 (es) | 2004-10-27 |
| CN1553815A (zh) | 2004-12-08 |
| HUP0400115A3 (en) | 2005-11-28 |
| PL367624A1 (en) | 2005-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5560585A2 (es) | Formulacion farmaceutica para administracion intramuscular de fulvestrant | |
| CY1121133T1 (el) | Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα | |
| NO970068L (no) | Inhaleringssammensetning | |
| AR098109A2 (es) | Un análogo de epotilona, su uso para la preparación de un medicamento y una composición farmacéutica adecuada para administración parenteral | |
| NO20032510L (no) | Organiske forbindelser | |
| PH12013500419A1 (en) | Pharmaceutical composition for the treatment or prevention of diseases involving diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| CR7938A (es) | Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico | |
| CA2215327A1 (en) | Formulations for lipophilic compounds | |
| AR045094A1 (es) | Formulaciones liofilizadas de cci-779 | |
| PA8532001A1 (es) | Bifenilcarboxamidas utiles como agentes reductores de lipidos | |
| AR027360A1 (es) | Composicion farmaceutica | |
| GT200100063A (es) | El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoariaen mamiferos | |
| WO2007099410A3 (en) | Formulations of fispemifene | |
| UA93365C2 (ru) | Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты) | |
| BR0108313A (pt) | Composição farmacêutica para injeção intramuscular contendo loxoprofeno | |
| ES2170649B1 (es) | Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica. | |
| DE602004014964D1 (de) | Pharmazeutische zusammensetzung mit einem kationischen hilfsmittel | |
| AR027286A1 (es) | Preparacion farmaceutica estable de oxaliplatina para administracion por via parenteral y procedimiento para preparar dicha preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |